PMID- 9809623
OWN - NLM
STAT- MEDLINE
DCOM- 19990226
LR  - 20131121
IS  - 1079-9907 (Print)
IS  - 1079-9907 (Linking)
VI  - 18
IP  - 10
DP  - 1998 Oct
TI  - Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients 
      with myelodysplastic syndromes.
PG  - 871-7
AB  - Tumor necrosis factor-alpha (TNF-alpha) levels were measured in the serum 
      (sTNF-alpha) or bone marrow (BM) biopsies of 43 patients with myelodysplastic 
      syndromes (MDS) who subsequently received therapy with a combination of 
      pentoxifylline and ciprofloxacin (PC) with or without dexamethasone (PCD). All 43 
      patients received only PC therapy for 12 weeks, after which 18 of 36 
      nonresponders received PCD. A total of 18 of 43 patients showed a hematologic or 
      cytogenetic response or both. BM TNF-alpha levels were semiquantitatively 
      assessed using immunohistochemistry on a scale of 0-8+ and in the serum using 
      enzyme linked immunoassay. The median TNF-alpha for the entire group was 3.0 in 
      BM and 6.9 pg/ml in the serum, and 14 patients had no detectable levels. 
      Responders had higher BM levels (median 3.5 vs. 2.0) than nonresponders, although 
      this was not statistically significant. During PC therapy, a decline in BM 
      TNF-alpha level was seen in the entire group, which was significant at 2 weeks (p 
      = 0.02), 8 weeks (p = 0.001), and 12 weeks (p = 0.0001). Both responders (p = 
      0.01) and nonresponders (p = 0.03) had a decline at 8 weeks, but at 12 weeks, 
      only the responders continued to show a significant decline (p = 0.03). We 
      conclude that MDS patients with high BM TNF-alpa levels have a better chance of 
      responding to PCD therapy and that the therapy is quite successful in reducing 
      the TNF-alpha levels in a sustained fashion. Future studies need to be directed 
      at identifying agents that would be more potent suppressors of the proapoptotic 
      cytokines in these patients.
FAU - Reza, S
AU  - Reza S
AD  - Rush Cancer Institute, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 
      60612-3515, USA.
FAU - Shetty, V
AU  - Shetty V
FAU - Dar, S
AU  - Dar S
FAU - Qawi, H
AU  - Qawi H
FAU - Raza, A
AU  - Raza A
LA  - eng
GR  - P01CA 75606/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 5E8K9I0O4U (Ciprofloxacin)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Ciprofloxacin/*therapeutic use
MH  - Dexamethasone/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hematologic Tests
MH  - Humans
MH  - Karyotyping
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*drug therapy/metabolism
MH  - Pentoxifylline/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/*metabolism
EDAT- 1998/11/11 00:00
MHDA- 1998/11/11 00:01
CRDT- 1998/11/11 00:00
PHST- 1998/11/11 00:00 [pubmed]
PHST- 1998/11/11 00:01 [medline]
PHST- 1998/11/11 00:00 [entrez]
AID - 10.1089/jir.1998.18.871 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 1998 Oct;18(10):871-7. doi: 10.1089/jir.1998.18.871.